drug
(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide)
Marketedupdated 5mo agoby $GILD GILEAD SCIENCES, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 15, 2032
~5.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Feb 15, 2033patentUS 8754065*PED
- Feb 15, 2033patentUS 9296769*PED
- Aug 15, 2032compositionUS 8754065
- Aug 15, 2032compositionUS 9296769
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that